OCU-400 is a gene therapy commercialized by Ocugen, with a leading Phase II program in Retinitis Pigmentosa (Retinitis);Leber Congenital Amaurosis (LCA). According to Globaldata, it is involved in 2 clinical trials, of which 1 is ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of OCU-400’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData


Premium Insights Net Present Value Model: Ocugen Inc's OCU-400

Buy the Model

Premium Insights

The gold standard of business intelligence.

Find out more

The revenue for OCU-400 is expected to reach an annual total of $177 mn by 2038 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

OCU-400 Overview

OCU-400 is under development for the treatment of inherited degenerative retinal diseases (IRDs) such as NR2E3, CEP290, PDE6B and RHO mutation-associated recessive retinal degeneration, Leber Congenital Amaurosis (LCA), Bardet-Biedl Syndrome (BBS), enhanced S-cone syndrome and rhodopsin mutations associated retinitis pigmentosa and other retinal degenerations. It is administered as sub-retinal injection. The therapeutic candidate is an adeno-associated virus serotype 5 capsid containing the gene for human nuclear hormone receptor NR2E3. It is developed based on modifier gene therapy platform. It acts by targeting centrosomal protein of 290 kDa (CEP290) and Rhodopsin

Ocugen Overview

Ocugen Is a biopharmaceutical company that discovers, develops and commercializes drugs for treatment. It is investigating OCU-400 against NR2E3, RHO, CEP290, and PDE6B mutation-associated retinal degeneration; and OCU-410 targeting dry age-related macular degeneration. The company is developing OCU200 drugs to treat diabetic macular edema, diabetic retinopathy, and wet-age-related macular degeneration. Ocugen is also investing OCU410ST for stargardt orphan disease. It utilizes a modified gene therapy platform to develop its products. The company operates in Ireland and the US. Ocugen is headquartered in Malvern, Pennsylvania, the US.
The operating loss of the company was US$84.9 million in FY2022, compared to an operating loss of US$57.6 million in FY2021. The net loss of the company was US$81.4 million in FY2022, compared to a net loss of US$58.4 million in FY2021.

For a complete picture of OCU-400’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 22 April 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.